| Gene symbol | MSLN | Synonyms | MPF, SMRP | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | mesothelin | ||||
| GTO ID | GTC2630 |
| Trial ID | NCT04809766 |
| Disease | Pancreatic Ductal Adenocarcinoma |
| Altered gene | MSLN |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Mesothelin TCR-T cells |
| Co-treatment | Bendamustine |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I Study of Autologous Transgenic T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR TMSLN) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma |
| Year | 2021 |
| Country | United States |
| Company sponsor | Fred Hutchinson Cancer Center |
| Other ID(s) | RG1007292|NCI-2020-08496|10417 |
| Cohort1: TCR-T_Bendamustine | |||||||||
|
|||||||||
| Cohort2: TCR-T | |||||||||
|
|||||||||